argenx SE (ARGNF)
USD 697.42
(0.33%)
USD 697.42
(0.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -295.05 Million USD | 58.42% |
| 2022 | -709.59 Million USD | -73.81% |
| 2021 | -408.26 Million USD | 37.24% |
| 2020 | -650.54 Million EUR | -256.37% |
| 2019 | -182.54 Million EUR | -139.47% |
| 2018 | -76.23 Million EUR | -126.32% |
| 2017 | -33.68 Million EUR | -49.84% |
| 2016 | -22.47 Million EUR | -34.28% |
| 2015 | -16.74 Million EUR | -33.48% |
| 2014 | -12.54 Million EUR | -48.14% |
| 2013 | -8.46 Million EUR | 33.99% |
| 2012 | -12.82 Million EUR | -185.59% |
| 2011 | -4.49 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -32.48 Million USD | 47.27% |
| 2024 Q1 | -61.59 Million USD | 37.98% |
| 2023 Q1 | -28.87 Million USD | 25.23% |
| 2023 Q2 | -94.36 Million USD | -226.86% |
| 2023 FY | -295.05 Million USD | 58.42% |
| 2023 Q4 | -99.31 Million USD | -36.72% |
| 2023 Q3 | -72.64 Million USD | 23.02% |
| 2022 Q4 | -38.61 Million USD | 83.57% |
| 2022 Q2 | -208.74 Million USD | 8.12% |
| 2022 Q1 | -227.18 Million USD | 4.47% |
| 2022 Q3 | -235.04 Million USD | -12.6% |
| 2022 FY | -709.59 Million USD | -73.81% |
| 2021 FY | -408.26 Million USD | 37.24% |
| 2021 Q1 | -40.43 Million EUR | -114.0% |
| 2021 Q2 | 103.6 Million USD | 356.23% |
| 2021 Q3 | -233.61 Million USD | -325.5% |
| 2021 Q4 | -237.81 Million USD | -1.8% |
| 2020 Q4 | 288.9 Million USD | 283.25% |
| 2020 Q3 | -157.65 Million EUR | 0.0% |
| 2020 FY | -650.54 Million EUR | -256.37% |
| 2019 FY | -182.54 Million EUR | -139.47% |
| 2019 Q1 | 7.57 Million EUR | 122.36% |
| 2019 Q2 | -58.88 Million EUR | -876.89% |
| 2019 Q3 | -24.93 Million EUR | 57.65% |
| 2019 Q4 | -92.9 Million EUR | -272.59% |
| 2018 Q4 | -33.89 Million EUR | -77.2% |
| 2018 Q2 | -1.44 Million EUR | 93.37% |
| 2018 Q1 | -21.76 Million EUR | -51.72% |
| 2018 FY | -76.23 Million EUR | -126.32% |
| 2018 Q3 | -19.12 Million EUR | -1224.58% |
| 2017 Q1 | -8.98 Million EUR | -7.25% |
| 2017 FY | -33.68 Million EUR | -49.84% |
| 2017 Q4 | -14.34 Million EUR | -44.05% |
| 2017 Q3 | -9.96 Million EUR | -2470.1% |
| 2017 Q2 | -387.54 Thousand EUR | 95.69% |
| 2016 Q4 | -8.37 Million EUR | -41.6% |
| 2016 FY | -22.47 Million EUR | -34.28% |
| 2016 Q3 | -5.91 Million EUR | -22.86% |
| 2016 Q2 | -4.81 Million EUR | -43.09% |
| 2016 Q1 | -3.36 Million EUR | 37.72% |
| 2015 FY | -16.74 Million EUR | -33.48% |
| 2015 Q4 | -5.4 Million EUR | -56.02% |
| 2015 Q3 | -3.46 Million EUR | 25.45% |
| 2015 Q2 | -4.64 Million EUR | -44.03% |
| 2015 Q1 | -3.22 Million EUR | 29.28% |
| 2014 FY | -12.54 Million EUR | -48.14% |
| 2014 Q4 | -4.56 Million EUR | -161.37% |
| 2014 Q2 | -3.67 Million EUR | -43.47% |
| 2014 Q1 | -2.56 Million EUR | -22.83% |
| 2014 Q3 | -1.74 Million EUR | 52.49% |
| 2013 Q3 | -102.69 Thousand EUR | 97.41% |
| 2013 Q2 | -3.95 Million EUR | -70.73% |
| 2013 Q4 | -2.08 Million EUR | -1930.17% |
| 2013 FY | -8.46 Million EUR | 33.99% |
| 2013 Q1 | -2.31 Million EUR | 0.0% |
| 2012 FY | -12.82 Million EUR | -185.59% |
| 2011 FY | -4.49 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -21994.215% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -4125.404% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 656.924% |
| Nascent Biotech, Inc. | -2.08 Million USD | -14033.043% |
| Rebus Holdings, Inc. | -1.02 Million USD | -28826.765% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 553.001% |
| Qrons Inc. | -789.34 Thousand USD | -37279.378% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -46555.556% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -371.338% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -70915.142% |
| Skye Bioscience, Inc. | -37.64 Million USD | -683.782% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -293.598% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -4386.74% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -107819.108% |
| SQZ Biotechnologies Company | -79.46 Million USD | -271.304% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -10100.996% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -16107.001% |
| Mesoblast Limited | -87.95 Million USD | -235.455% |
| Marizyme, Inc. | -65.34 Million USD | -351.518% |
| Genus plc | 7.9 Million USD | 3834.848% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -2608.961% |
| Pharming Group N.V. | -10.54 Million USD | -2697.241% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -13498.078% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -7852.409% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -3236.194% |
| ContraFect Corporation | -65.15 Million USD | -352.862% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -5938.665% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -16980.213% |
| IMV Inc. | -36.48 Million USD | -708.681% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -3560.852% |
| MultiCell Technologies, Inc. | -380.07 USD | -77631125.827% |
| ONE Bio Corp. | 8.67 Million USD | 3500.555% |
| Accustem Sciences Inc. | -3.74 Million USD | -7775.601% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -470.79% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -23185.067% |
| Q BioMed Inc. | -2.05 Million USD | -14278.15% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -7803.911% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -12292.655% |
| Biomind Labs Inc. | -1.21 Million USD | -24197.816% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -394.016% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -9412.414% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -3633.386% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -15036.753% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -1970072.276% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -1759.018% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -4972.033% |
| GB Sciences, Inc. | -1.36 Million USD | -21568.355% |
| Alpha Cognition Inc. | -13.77 Million USD | -2042.324% |
| HST Global, Inc. | -146.21 Thousand USD | -201700.834% |
| CSL Limited | 2.64 Billion USD | 111.168% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -16714.331% |
| Halberd Corporation | -79.67 Thousand USD | -370216.03% |
| Enzolytics Inc. | -2.17 Million USD | -13454.238% |
| Agentix Corp. | -1.37 Million USD | -21370.72% |
| Resverlogix Corp. | -3.61 Million USD | -8073.213% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -9203.451% |
| MetaStat, Inc. | - USD | Infinity% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 301174.49% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 4360.943% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -7326.467% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -9650.16% |
| AVAX Technologies, Inc. | -6.41 Million USD | -4500.393% |
| Zenith Capital Corp. | -10.59 Million USD | -2684.57% |
| Genscript Biotech Corporation | -95.47 Million USD | -209.03% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -1269381.972% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -7016.68% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -488070.123% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -14615.016% |
| Kadimastem Ltd | -3.3 Million USD | -8821.001% |
| Helix BioMedix, Inc. | -1.05 Million USD | -27839.117% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -7625.923% |
| BioStem Technologies, Inc. | -8.48 Million USD | -3378.175% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -66749.507% |
| LadRx Corporation | 400.44 Thousand USD | 73781.648% |
| Cell Source, Inc. | -5.32 Million USD | -5444.846% |
| Regen BioPharma, Inc. | 1.02 Million USD | 28927.62% |
| Regen BioPharma, Inc. | 1.02 Million USD | 28927.62% |
| NovAccess Global Inc. | -4.76 Million USD | -6086.652% |
| Affymax, Inc. | -14.42 Million USD | -1945.57% |
| Itoco Inc. | -1.86 Million USD | -15686.72% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -6541.546% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -17578.43% |
| Mobile Lads Corp. | -2.26 Million USD | -12936.453% |
| CytoDyn Inc. | -49.84 Million USD | -491.989% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -373228.863% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -129237.167% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -31237.643% |
| SYBLEU INC | -180.3 Thousand USD | -163541.96% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -18195.172% |
| International Stem Cell Corporation | -131 Thousand USD | -225131.298% |
| Bioxytran, Inc. | -4.28 Million USD | -6793.758% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -543556.029% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -11561.035% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -513.773% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -13857.096% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -37684.34% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -9213.542% |
| Neutra Corp. | -233.46 Thousand USD | -126279.971% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -1354.108% |
| PureTech Health plc | -65.69 Million USD | -349.112% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -1287.405% |
| IXICO plc | -1.17 Million USD | -24946.944% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -2872.227% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -416.477% |
| CSL Limited | 2.64 Billion USD | 111.168% |
| Cellectis S.A. | -103.17 Million USD | -185.977% |